In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Open to Innovation: A Conversation with Johnson & Johnson Pharma R&D Chief Paul Stoffels

Executive Summary

Johnson & Johnson believes its future success is directly dependent on its ability to access best-in-class science via more flexible, less risky partnerships. The health care giant's global head of pharmaceutical R&D, Paul Stoffels, explains in greater detail J&J's open innovation model.
Advertisement

Related Content

Best of the Blog February 2010
Best of the Blog February 2010
J&J Pushes New Treatment Paradigm for Invega Sustenna
New Frontiers in Pharma R&D Investment
New Frontiers in Pharma R&D Investment
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
Elan's High Wire Act Finds a Semi-Safe Net
Elan's High Wire Act Finds a Semi-Safe Net
The GSK/Pfizer HIV Venture: Another Sign of Change?
The GSK/Pfizer HIV Venture: Another Sign of Change?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel